E Fund Management’s Soleno Therapeutics SLNO Stock Holding History

E Fund Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,009	Closed	-$335K	–	515
2026 Q1	$335K	Buy	+10,009	New	+$392K	0.01%	366
2025 Q2	$443K	Buy	5,291 +959	+22%	+$71.8K	0.02%	245
2025 Q1	$310K	Sell	4,332 -371	-8%	-$18.1K	0.01%	306
2024 Q4	$211K	Buy	+4,703	New	+$244K	0.01%	356
2024 Q2	–	Sell	-5,016	Closed	-$215K	–	371
2024 Q1	$215K	Buy	+5,016	New	+$227K	0.01%	332

E Fund Management's SLNO Position: Q2 2026 in Review

E Fund Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 10,009 shares — an estimated $335K sold.

E Fund Management first reported a position in SLNO in Q1 2024 and held it in 5 quarters. The position peaked at $443K in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

E Fund Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
E Fund Management sold 10,009 Soleno Therapeutics shares in Q2 2026, an estimated $335K.
E Fund Management first reported a position in Soleno Therapeutics in Q1 2024 and held it in 5 quarters.
E Fund Management's Soleno Therapeutics position peaked at $443K in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.